BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30778048)

  • 1. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
    Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
    J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
    Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
    Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCNA-associated factor P15
    Jin C; Liu Z; Li Y; Bu H; Wang Y; Xu Y; Qiu C; Yan S; Yuan C; Li R; Diao N; Zhang Z; Wang X; Liu L; Kong B
    Int J Cancer; 2018 Dec; 143(11):2973-2984. PubMed ID: 30129654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
    Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
    Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
    Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
    Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
    J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVI1 overexpression promotes ovarian cancer progression by regulating estrogen signaling.
    Wang Z; Li Y; Wang N; Li P; Kong B; Liu Z
    Mol Cell Endocrinol; 2021 Aug; 534():111367. PubMed ID: 34146645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S; Chang H; Deng S; Fan D
    Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway.
    Yang QX; Zhong S; He L; Jia XJ; Tang H; Cheng ST; Ren JH; Yu HB; Zhou L; Zhou HZ; Ren F; Hu ZW; Gong R; Huang AL; Chen J
    Cancer Lett; 2019 Jun; 452():90-102. PubMed ID: 30914208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
    Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
    J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.
    Liu Z; Liu J; Li L; Nie D; Tao Q; Wu J; Fan J; Lin C; Zhao S; Ju D
    PLoS One; 2015; 10(8):e0135236. PubMed ID: 26288183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
    Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
    Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.